Acute cerebrovascular disease is one of the three leading causes of human death. Once a cerebral infarction occurs, the patient becomes hemiplegic or completely paralyzed, placing a great burden on society and the family. Cerebral infarction is caused by blood clots from other parts of the brain entering the arteries in the brain and blocking the blood vessels. 20% of stroke patients are caused by the dislodgement of blood clots in the heart during atrial fibrillation. And 75% of patients with atrial fibrillation are bound to have a cerebrovascular accident, resulting in a stroke. Atrial fibrillation is the most common heart rhythm disorder, which in layman’s terms means that the heart beats without rhythm. Patients often feel tightness in the chest and panic attacks. The incidence of atrial fibrillation is about 1% of the population, with an incidence of up to 10% in people over 70 years of age. The treatment of atrial fibrillation has been very complicated, and drug therapy is not effective and some patients cannot tolerate drug therapy. Catheter ablation therapy is prone to recurrence. The Department of Thoracic Surgery has recently developed the latest international technology for the treatment of atrial fibrillation using minimally invasive surgery: thoracoscopic radiofrequency ablation of minimally invasive atrial fibrillation. With the help of high-tech minimally invasive thoracoscopic techniques, surgeons can make only two to three small (1 to 2 cm long) incisions in the patient’s chest to complete the procedure, and the patient can be discharged two days after the procedure. Thoracoscopic minimally invasive radiofrequency ablation of atrial fibrillation is highly effective: with paroxysmal atrial fibrillation as the main treatment target, the overall cure rate can reach 91.3% at 6 months, and patients are not taking anti-arrhythmic drugs and anticoagulants; the overall cure rate is 80% at 2 years after surgery; and no postoperative stroke occurs. The current indications for minimally invasive surgical ablation for atrial fibrillation are: 1) patients aged 18-80 years; 2) patients with paroxysmal and isolated atrial fibrillation; 3) patients with significant symptoms of atrial fibrillation without serious organic heart disease, heart valve disease, coronary artery disease, etc. that require surgical treatment; 4) patients who are ineffective with antiarrhythmic drugs or who cannot tolerate drug therapy; 5) patients who have a history of Patients with contraindications to anticoagulation and antiplatelet therapy such as warfarin and aspirin; 6. Patients with previous history of thromboembolism, such as stroke or transient ischemic attack; 7. Patients with recurrence of atrial fibrillation after catheter ablation. The advantages of thoracoscopic minimally invasive radiofrequency ablation of atrial fibrillation include: 1) bilateral pulmonary vein isolation; linear ablation of the left atrium; vagus nerve ablation, etc. These operations are more intuitive, simple and effective than catheter ablation; 2) left auricular thrombosis in patients with left auricular thrombosis, which fundamentally eliminates the risk of thrombosis and embolism due to atrial fibrillation; 3) the procedure can perform intraoperative electrophysiological markings, such as ablation line through the wall The procedure can perform intraoperative electrophysiological markers, such as ablation wire through the wall, to make the ablation complete; 4. Ablation of the epicardial vagal ganglion. Currently, the role of autonomic nerve in the mechanism of atrial fibrillation is gaining attention, and the distribution is in the subepicardium. Catheter ablation cannot ablate the epicardial vagal ganglion. The development of this new technology will certainly bring benefits to patients with atrial fibrillation and greatly reduce the risk of cerebrovascular accidents.